Eli Lilly and Company

Eli Lilly

James Ronald Gillig

John M Schaus

Michael R Jirousek

Lawrence Joseph Heinz, Ii

John Michael Morin, Jr

Matthew Joseph Fisher

Bruno Giethlen

Michael Dean Kinnick

Nancy June Snyder

Jefferson Ray McCowan

Shawn Christopher Miller

Zhaogen Chen

Michael Philip Cohen

Yen-Shi Lai

Philip Arthur Hipskind

John S Ward

Timothy Paul Burkholder

Michael E Flaugh

Theo Schotten

Sandra Ann Filla

Kenneth Allen Savin

Joseph H Krushinski, Jr

James Arthur Nixon

Serge Louis Boulet

Zhipei Wu

Bin Liu

Michael Alan Robertson

Raymond Gilmour

Marta Maria Pineiro-Nunez

Renato Alejandro Bauer

Santiago Carballares Martin

Carsten Ott

Jochen Ammenn

Wenceslao Lumeras

Lawrence John Slieker

John Mehnert Schaus

Jefferson Ray Mccowan

Wenceslao Aka Lumeras Amador Wenceslao Lumeras

Phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds of Formula I, formulations containing those compounds, and their use as mutant isocitrate dehydrogenase 1 enzyme inhibitors. 

7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors

The present invention provides compounds of formula (I), which are antagonists of the 5-HTreceptor. 

N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor

The present invention relates to a melanin concentrating hormone antagonist compound of formula I: (I); or a pharmaceutically acceptable salt, solvate, enantiomer or prodrug thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.

Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes

The present invention relates to compounds of formula I: which are antagonists of 5-HT6 receptor. 

[object Object]

The present invention provides compounds of formula I pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are antagonists of the 5-HTreceptor. The present invention further provides a method of treating disorders associated with 5-HTreceptors, including schizophrenia, anxiety, Alzheimer's disease, and cognitive disorders selected from the group consisting of age-related cognitive decline, mild cognitive impairment, and dementia, comprising: administering to a patient in need thereof an effective amount of a compound of formula I.

The present invention relates to a melanin concentrating hormone antagonist compound of Formula I: (I) wherein Ar, Ar, Ar, L, Land Q areas defined, or a pharmaceutically acceptable salt, solvate, enantiomer or mixture of diastereomers thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and Related Diseases 

MCH receptor antagonists

The present invention provides an efficient process of reacting a bis-indolyl acid of the Formula (II): ##STR1## wherein R.sup.1 is a hydrogen or C.sub.1 -C.sub.4 alkyl and R, X, and Y are optional substitutions; to produce a bis-indolyloxallic acid of the Formula (III): ##STR2## Compounds of the Formula (III) are readily converted to the bis-indolylmaleimides.

Synthesis of bisindolylmaleimides

The present invention discloses compounds that are highly isozyme selective protein kinase C beta-1 and beta-2 isozyme inhibitors. The present invention also provides a method of selectively inhibiting protein kinase C isozymes beta-1, and beta-2. As isozyme selective inhibitors of beta-1 and beta-2, the compounds are therapeutically useful in treating conditions associated with diabetes mellitus and its complications, as well as other disease states associated with an elevation of the beta-1 and beta-2 isozyme.

Protein kinase C inhibitors

Growing community of inventors

Indianapolis, IN, United States of America

James Ronald Gillig